Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of April 2025, with a report date of April 15, 2025. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price (GBP) | Volume | Transaction Type |
|---|---|---|---|---|
| 2025-04-11 | Ordinary Shares (ISIN: GB00BN7SWP63) | 12.7300 | 25 | Acquisition via Dividend Re-investment (ISA) |
| 2025-04-11 | Ordinary Shares (ISIN: GB00BN7SWP63) | 12.7300 | 22 | Acquisition via Dividend Re-investment (ISA) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine share acquisitions resulting from dividend re-investment plans for two individuals.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific transactions executed on the London Stock Exchange (XLON).
Key Facts for Investor Verification
- Dividend Re-investment: Two PDMRs (David Redfern, President Corporate Development; Victoria Whyte, Company Secretary) acquired shares on April 11, 2025, via dividend re-investment.
- Transaction Volume: A total of 47 Ordinary Shares were acquired across both transactions at a price of £12.7300 per share.
- Account Type: The shares were held within an Individual Savings Account (ISA).
- No Financial Data: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.